Market Overview

IGC to Enter California Market with Hyalolex


India Globalization Capital, Inc. (NYSE:IGC) announces that it
has designated California as a priority market for Hyalolex, its lead
cannabis-based supplement for treating and managing Alzheimer's patients.

"The cannabis market is showing explosive growth and we are aggressively
moving forward with our vision of owning and marketing the leading
brands for large medical indications such as Alzheimer's, Parkinson's,
PTSD, pain, veterinary medicine and cancer. With 8 patents filed, IGC
has made significant strides towards achieving these goals and building
value for our shareholders as a NYSE American listed company," stated
Ram Mukunda, CEO of IGC.

"California is considered to be the largest addressable U.S. market for
cannabis with an environment that strongly embraces its acceptance. This
represents a significant opportunity for Hyalolex and our brands, as
such we are currently coordinating the necessary steps to efficiently
and rapidly introduce our product to high-density regions in the state.
It should be noted that according to U.S. Census data, California has an
estimated population of 39.54 million and that total is larger than all
of Canada," continued Mukunda.

IGC's management team has been actively meeting with California-based
manufacturers and distributers to assemble the requisite combination of
partners to efficiently bring Hyalolex to dispensaries, patients and
caregivers in California. Our "Drops of Clarity" marketing program will
highlight the potential benefits of Hyalolex as a supplement to cannabis
physicians as well as to caregivers and patients via both a digital
format and through grassroots outreach.

About IGC

IGC has two lines of business, a legacy infrastructure business and a
cannabis pharmaceutical business that has developed a lead product for
Alzheimer's patients. The Company recently announced that it is working
on using blockchain to address issues specific to the cannabis industry
that address transactional difficulties, product labeling, product
identification assurance (PIA), and product origin assurance (POA). The
company is based in Maryland, USA.

Our website:
Twitter @IGCIR

About Alzheimer's disease

Alzheimer's disease (AD) is a form of dementia. It is known as America's
most expensive disease, with an estimated cost to the U.S. economy of
$236 billion. AD currently affects more than 5.3 million Americans and
over 66% of AD patients are women.

Forward-looking Statements

Please see forward looking statements as discussed in detail in IGC's
Form 10K for fiscal year ended March 31, 2018, and in other reports
filed with the U.S. Securities and Exchange Commission.

View Comments and Join the Discussion!